268 related articles for article (PubMed ID: 18374188)
1. VKORC1 and the vitamin K cycle.
Garcia AA; Reitsma PH
Vitam Horm; 2008; 78():23-33. PubMed ID: 18374188
[TBL] [Abstract][Full Text] [Related]
2. Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction.
Wajih N; Hutson SM; Wallin R
J Biol Chem; 2007 Jan; 282(4):2626-35. PubMed ID: 17124179
[TBL] [Abstract][Full Text] [Related]
3. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
[TBL] [Abstract][Full Text] [Related]
4. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin.
Rost S; Fregin A; Hünerberg M; Bevans CG; Müller CR; Oldenburg J
Thromb Haemost; 2005 Oct; 94(4):780-6. PubMed ID: 16270630
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle.
Oldenburg J; Bevans CG; Müller CR; Watzka M
Antioxid Redox Signal; 2006; 8(3-4):347-53. PubMed ID: 16677080
[TBL] [Abstract][Full Text] [Related]
6. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
Loriot MA; Beaune P
Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
[TBL] [Abstract][Full Text] [Related]
7. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system.
Wajih N; Sane DC; Hutson SM; Wallin R
J Biol Chem; 2005 Mar; 280(11):10540-7. PubMed ID: 15640149
[TBL] [Abstract][Full Text] [Related]
8. VKCFD2 - from clinical phenotype to molecular mechanism.
Czogalla KJ; Watzka M; Oldenburg J
Hamostaseologie; 2016 Nov; 36(Suppl. 2):S13-S20. PubMed ID: 27824210
[TBL] [Abstract][Full Text] [Related]
9. The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif.
Czogalla KJ; Biswas A; Rost S; Watzka M; Oldenburg J
Blood; 2014 Aug; 124(8):1354-62. PubMed ID: 24963046
[TBL] [Abstract][Full Text] [Related]
10. Structural Modeling Insights into Human VKORC1 Phenotypes.
Czogalla KJ; Watzka M; Oldenburg J
Nutrients; 2015 Aug; 7(8):6837-51. PubMed ID: 26287237
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of protein disulfide isomerase enhances vitamin K epoxide reductase activity.
Chetot T; Benoit E; Lambert V; Lattard V
Biochem Cell Biol; 2022 Apr; 100(2):152-161. PubMed ID: 35007172
[TBL] [Abstract][Full Text] [Related]
12. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding.
Spohn G; Kleinridders A; Wunderlich FT; Watzka M; Zaucke F; Blumbach K; Geisen C; Seifried E; Müller C; Paulsson M; Brüning JC; Oldenburg J
Thromb Haemost; 2009 Jun; 101(6):1044-50. PubMed ID: 19492146
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
[TBL] [Abstract][Full Text] [Related]
14. VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors.
Wallin R; Wajih N; Hutson SM
Vitam Horm; 2008; 78():227-46. PubMed ID: 18374197
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K epoxide reductase: homology, active site and catalytic mechanism.
Goodstadt L; Ponting CP
Trends Biochem Sci; 2004 Jun; 29(6):289-92. PubMed ID: 15276181
[TBL] [Abstract][Full Text] [Related]
16. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
17. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
Siguret V; Pautas E; Gouin-Thibault I
Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
[TBL] [Abstract][Full Text] [Related]
18. The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation.
Rishavy MA; Hallgren KW; Wilson LA; Usubalieva A; Runge KW; Berkner KL
J Biol Chem; 2013 Nov; 288(44):31556-66. PubMed ID: 23918929
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of vitamin K epoxide reductase.
Tie JK; Stafford DW
Vitam Horm; 2008; 78():103-30. PubMed ID: 18374192
[TBL] [Abstract][Full Text] [Related]
20. VKORC1: molecular target of coumarins.
Oldenburg J; Watzka M; Rost S; Müller CR
J Thromb Haemost; 2007 Jul; 5 Suppl 1():1-6. PubMed ID: 17635701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
